Linclatamig

N/A

Report date: 2026/03/19 17:23:40

Base Information

Drug NameLinclatamig

Drug Alias NameBLYG-8824BLYG-8824ARG 6286

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT-cell surface glycoprotein CD3 epsilon chain inhibitorsLymphocyte antigen 6 complex locus protein G6d inhibitors

TargetsT-cell surface glycoprotein CD3 epsilon chainLymphocyte antigen 6 complex locus protein G6d

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaSpain

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGenentech Inc

China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A